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Abstract The clinical manifestations of anti-cancer drug
associated cardiac side effects are diverse and can range
from acutely induced cardiac arrhythmias to Q–T interval
prolongation, changes in coronary vasomotion with con-
secutive myocardial ischemia, myocarditis, pericarditis,
severe contractile dysfunction, and potentially fatal heart
failure. The pathophysiology of these adverse effects is
similarly heterogeneous and the identification of potential
mechanisms is frequently difficult since the majority of
cancer patients is not only treated with a multitude of
cancer drugs but might also be exposed to potentially
cardiotoxic radiation therapy. Some of the targets inhibited
by new anti-cancer drugs also appear to be important for
the maintenance of cellular homeostasis of normal tissue,
in particular during exposure to cytotoxic chemotherapy. If
acute chemotherapy-induced myocardial damage is only
moderate, the process of myocardial remodeling can lead
to progressive myocardial dysfunction over years and
eventually induce myocardial dysfunction and heart failure.
The tools for diagnosing anti-cancer drug associated car-
diotoxicity and monitoring patients during chemotherapy
include invasive and noninvasive techniques as well as
laboratory investigations and are mostly only validated for
anthracycline-induced cardiotoxicity and more recently for
trastuzumab-associated cardiac dysfunction.
Keywords Cardiotoxicity  Cancer  Anthracycline 
Trastuzumab  Diagnosis  Cardiomyocytes
Introduction
The clinical manifestations of anti-cancer drug associated
cardiac side effects are diverse and can range from acutely
induced cardiac arrhythmias to Q–T interval prolongation,
changes in coronary vasomotion with consecutive myo-
cardial ischemia, myocarditis, pericarditis, severe contrac-
tile dysfunction, and potentially fatal heart failure. The
pathophysiology of these adverse effects is similarly het-
erogeneous and the identification of potential mechanisms
is frequently difficult since the majority of cancer patients
is not only treated with a multitude of cancer drugs but
might also be exposed to potentially cardiotoxic radiation
therapy. The long-term prognosis of cancer survivors not
only depends on the efficacy of the anti-cancer therapy, but
is also influenced by treatment-associated, irreversible side
effects. The cardiovascular side effects are important since
they can lead to chronic and progressive cardiac disease
and therefore might significantly impair long-term prog-
nosis of cancer survivors. In particularly, the chemother-
apy-associated cardiomyopathy and heart failure have a
bad prognosis and should be avoided whenever possible.
The pathophysiological mechanisms leading to chemo-
therapy-induced cardiomyopathy are mainly associated
with myocardial cell loss, either due to apoptosis or
necrosis. This cell loss is the net result of the direct car-
diotoxic effects of the cancer therapy on one side and
myocardial endogenous cardioprotective mechanisms such
as activation of antioxidative capacity, growth factors, ni-
tric oxide, gp130 and the neuregulin/ErbB signaling system
on the other side. If the extent of myocardial cell loss is
significant, contractile dysfunction might appear months
after chemotherapy. Alternatively, if acute chemotherapy-
induced myocardial damage is only moderate, a process
called myocardial remodeling can take years leading to
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progressive myocardial dysfunction and eventually heart
failure. However, it is also important to note, that acute
cancer drug-associated cardiac dysfunction can be induced
by structural changes of the myocardial contractile proteins
which are reversible and therefore may not lead to long-
term cardiac dysfunction [1].
Clinical manifestation of cancer drug associated
cardiotoxicity
One of the clinically most important cancer drug induced
cardiac side effects is anthracycline-associated cardiomy-
opathy. Anthracyclines were discovered in the 1960s and
remain one of the mainstays of modern cancer therapy.
Solid tumors such as breast cancer, sarcoma, ovarian and
bronchogenic carcinoma as well as lymphoma, and certain
forms of leukemia are some of the malignancies treated
with anthracyclines. The anti-cancer mechanisms of anth-
racyclines are not completely understood but likely include
inhibition of DNA replication by intercalating between the
base pairs and modifications of cellular proteins and
organelles by induction of free oxygen radicals. Free rad-
ical production also appears to be a major mechanism of
anthracycline-associated cardiac dysfunction.
Manifestation of anthracycline-associated cardiac tox-
icity (Table 1) can be diverse. Early cardiac side effects
occur within hours to days following therapy and typically
include arrhythmias, ECG changes, and infrequently peri-
carditis and myocarditis. These manifestations usually re-
spond promptly to the cessation of anthracycline infusion
and rarely preclude further continuation of anthracycline
treatment. Chronic or late anthracycline cardiotoxicity
typically manifests months or years after chemotherapy
and most frequently leads to cardiomyopathy with a bad
prognosis for the affected patients. Indeed, survival of
patients with anthracycline-associated heart failure is
worse than that of patients with ischemic or dilated car-
diomyopathy [2]. Furthermore, loss of myocardium,
regardless of the etiology, usually induces myocardial
remodeling, a relentless process eventually leading to end-
stage heart failure. Evidence from patients with ischemic
and dilated cardiomyopathies suggests that this remodeling
is, among others, mediated by the activation of the renin-
angiotensin-aldosteron (RAA) and adrenergic system and
that treatment with ACE-inhibitors, angiotensin receptor
blockers (ARB), aldosterone antagonists, and beta blockers
can slow the progression of disease [3]. It is therefore,
reasonable to suggest treating patients with anthracycline-
associated systolic dysfunction or heart failure with RAA
inhibitors and beta-blockers, despite limited data on their
effectiveness in these patients.
There are several known risk factors for anthracycline
(or more specifically doxorubicin) - associated cardiotox-
icity (Table 2). The cumulative dose appears to be the most
important one and recent data suggest that the risk of
anthracycline-associated heart failure is higher than ini-
tially estimated [4]. The incidence of doxorubicin-induced
heart failure increases linearly and reaches approximately
5% at a cumulative dose of 400–450 mg/m2. At higher
cumulative doses the risk increases exponentially and
children, women, and older (>65 years) patients appear to
be more sensitive [5]. Other risk factors for anthracycline-
induced cardiotoxicity include combination cancer therapy,
prior or concomitant mediastinal radiotherapy, previous
cardiac disease, and hypertension [6].
Several non-anthracycline based cancer drugs have also
been associated with significant cardiac side effects. An
overview of the most important cancer drugs is shown in
Table 3.
Pathophysiology of anthracycline-induced
cardiotoxicity
Anthracyclines and their related compounds are among the
best-characterized chemotherapeutic drugs leading to
myocardial cell loss [5–8]. Myocyte damage has been
attributed to a concentration-dependent increase of intra-
cellular oxidative stress with a consecutive increase in
cytosolic calcium, mitochondrial dysfunction (reviewed in
[9]), and induction of myocyte apoptosis or necrosis [10–
14]. Several studies have addressed the role of reactive
oxygen species (ROS) as a mediator of anthracycline-in-
duced damage to the heart. ROS not only lead to cell death,
but also directly affect excitation-contraction coupling and
Table 1 Clinical manifestation of anthracycline-associate cardio-
toxicity
Acute anthracycline cardiotoxicity
Onset Hours–days following therapy
Manifestation ECG changes
Arrhythmias
Pericarditis (infrequent)
Myocarditis (infrequent)
Importance Usually resolves after cessation of infusion
Rarely precludes further treatment
with anthracyclines
Sub-acute / chronic cardiotoxicity
Onset
Subacute Months following therapy
Chronic Months–years following therapy
Manifestation Contractile dysfunction and heart failure
Importance Progressive disease requiring therapy
Prognosis worse than other forms
of cardio-myopathies
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calcium signaling in cardiomyocytes. Effects of ROS on L-
type calcium channels [15], sarcoplasmic reticulum ATPase
[16], ryanodine receptors [17], and Na+/Ca2+ exchanger
activity [18] have been reported. An increase in intracellular
calcium after doxorubicin-treatment causes activation of the
endogenous protease calpain-1, which specifically degrades
the muscle protein titin in cultured adult rat ventricular
cardiomyocytes [19]. This finding in cell culture models
may explain one of the most prominent histological features
of anthracycline-induced cardiomyopathy in patients, the
loss of myofibrils. Recently, depletion of the transcription
factor GATA4 by anthracyclines has been found, which
could lead to apoptosis on the one hand and to downregu-
lation of important cardiac genes on the other hand [20].
Counteracting, compensatory mechanisms can include
induction and activation of endogenous antioxidant
enzymes, such as glutathione peroxidase, metallothionein,
cyclooxygenase-2 and possibly nitric oxide and the survival
factor neuregulin-1, which is released from microvascular
endothelial cells under stress conditions [21–27]. The
cumulative loss of myocardial cells and the exhaustion of
compensatory mechanisms over time might explain the
clinical observation that the cummulative dose is a strong
predictor of anthracycline associated cardiac dysfunction.
Cardiotoxicity of newer cancer therapeutics
Significant side effects have been limiting cytotoxic chemo-
therapies since their introduction, but newly developed,
Table 2 Risk factors for anthracycline and trastuzumab-associated cardiotoxicity
Anthracycline-associated cardiotoxicity Trastuzumab-associated cardiotoxicity
Cumulative dose 400–450 mg/m2 doxorubicin induces
heart failure in 5% of patients
Age >65 years and children at higher risk Age >50 years
Concomitant cancer
therapy
Cyclophosphamide Taxanes
Trastuzumab
Concomitant or prior
cancer therapy
Anthracyclines Paclitaxel
Radiation therapy Mediastinal, prior and concomitant
Previous cardiac disease Previous cardiac
disease
Reduced LV ejection fraction prior
trastuzumab
Hypertension
Table 3 Important cancer drugs with cardiac side effects
Drug Toxic dose range Mechanism of cardiac toxicity Type of cardiotoxicity
Anthracyclines
Doxorubicin
Daunorubicin
Epirubicin
>450 mg/m2 total
dose
>900 mg/m2
Free radical formation, DNA
intercalation
Contractile dysfunction arrhythmias
Antimetabolites
5-Fluorouracil
Capecitabine
Conventional dose Coronary artery vasospasm Angina/myocardial infarction
Microtubule
targeting drugs
Taxanes
Vinca alkaloids
Conventional dose Microtubule stabilization, myofibrillar
disarray
Microtubule modulation
Bradycardia, cardiomyopathy in combination with
doxorubicin and trastuzumab
Myocardial infarction
Alkylating drugs
Cyclophosphamide
>100–120 mg/kg over
2 days
Alkylating agent Hemorrhagic myocarditis, cardiomyopathy
Anti-HER2 drugs
Trastuzumab
Lapatinib
Conventional dose Myofibrillar disarray
Combined Tyrosine Kinase Inhibitor
Contractile dysfunction
Contractile dysfunction
BCR-ABL inhibitor
Imatinib
Conventional dose Inhibition of mitochondrial function,
oxidative stress
Contractile dysfunction?
Anti-angiogenic
Bevacizumab
Conventional dose Antibody binding VEGF Hypertension, myocardial infarction
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so-called targeted therapies have recently opened up new
possibilities in cancer therapy. Advances in the understanding
of cancer biology at the molecular level have identified
important signaling pathways, which are involved in cancer
cell division, cell–cell interaction and the formation of new
blood vessels in tumors. New biological therapeutics were
then developed with the goal to specifically inhibit selected
targets and to stop cancer cell proliferation and metastasis.
These targeted therapies were thought to be more effective
than traditional chemotherapeutic treatments and less harmful
to non-cancerous cells. However, most of these new biological
therapeutics per se are not cytotoxic and, therefore, need to be
combined with traditional chemotherapeutics and radiation
therapy. Furthermore, some of the targets inhibited by these
new anti-cancer drugs appear also to be important for the
maintenance of cellular homeostasis of normal tissue, in
particular during exposure to cytotoxic chemotherapy.
Some of the new biological anti-cancer drugs associated
with myocardial contractile dysfunction are trastuzumab,
imatinib, and possibly bevacizumab ([28–30]; Table 3).
Trastuzumab, an anti-HER2/erbB2 immunotherapeutic agent
used in HER2-overexpressing breast cancer patients, has
synergistic efficacy when used together with or after chemo-
therapeutic agents [31] and leads to tumor regression in
metastatic disease and to an impressive reduction in the risk of
recurrence when used as adjuvant therapy [32]. Unfortunately,
the combination of trastuzumab with cytotoxic agents, in
particular anthracyclines, bares a significant risk of cardio-
toxicity [28, 33]. Multivariate analysis for the development
of cardiac dysfunction in the pivotal trastuzumab trials iden-
tified concomitant use of anthracyclines, prior anthracycline
exposure, age >50 years, and prior cardiac disease as inde-
pendent risk factors (Table 2). Many of these risk factors are
similar to those for doxorubicin-induced cardiac dysfunction,
suggesting that the erbB2/neuregulin system might modulate
anthracycline-associated cardiac toxicity. Indeed, we have
recently demonstrated that signaling via the erbB2 receptor
can modulate doxorubicin-induced oxidative stress and
myofibrillar structural damage in vitro [19, 34, 35]. However,
in contrast to anthracycline-induced cardiomyopathy, trast-
uzumab-associated cardiac dysfunction appears to be mostly
reversible and non-progressive [1, 36]. Finally, combination
therapy of trastuzumab with paclitaxel bares also an increased
risk of cardiac contractile dysfunction [37], likely due to
paclitaxel-induced myofibrillar structural damage secondary
to attenuated basal phosphorylation of the Erk1/2 kinase and
increased oxidative stress [35].
Diagnosis of anti-cancer drug associated cardiotoxicity
The tools for diagnosing anti-cancer drug associated car-
diotoxicity and monitoring patients during chemotherapy
include invasive and noninvasive techniques as well as
laboratory investigations and are mostly only validated for
anthracycline-induced cardiotoxicity and more recently for
trastuzumab-associated cardiac dysfunction. It is important
to differentiate between transient, reversible cardiac dys-
function, and non-reversible cardiac damage but frequently
only the course over time allows differentiating between
the two forms. The methods, which have a predictive value
are endomyocardial biopsy and, less well documented, the
release of serum markers such as troponin and natriuretic
peptides (ANP, BNP), and heart rate variability.
The acute and subacute type of anthracycline-induced
cardiotoxicity can occur immediately after treatment and is
characterized by electrocardiographic changes (various
tachycardias, including flattening of the T-wave, prolon-
gation of the Q–T interval, and a decreased amplitude of
the R-wave) and reversible depression of ventricular con-
tractile function [7, 38]. Although dysrhythmias are rec-
ognized often in early doxorubicin cardiotoxicity, they are
seldom a concern in late toxicity unless they occur as a
component of severe heart failure. Right ventricular en-
domyocardial biopsy allows a correlation between myo-
cardial structural abnormalities and contractile dysfunction
and is the gold standard for the diagnosis of anthracycline-
associated cardiotoxicity [8]. Morphological changes de-
scribed in the myocardium are initial vacuole formation
and myofibrillar dropout and, at later stages, myocyte
necrosis. However, the relatively high technical and
logistical effort for this invasive procedure makes it less
attractive for daily clinical routine. The release of troponin
is associated with myocyte cell death and has also been
shown to be a predictive factor for cardiac dysfunction,
particularly in children when measured serially [39]. The
increase of natriuretic peptides reflects an elevation of the
(left or right) ventricular end diastolic pressure and has
been shown to be of predictive value for anthracycline
associated cardiac dysfunction [40, 41].
The most widely used technique for monitoring and
diagnosing anti-cancer drug associated cardiac dysfunction
is the noninvasive assessment of the left ventricular ejec-
tion fraction at rest by radionuclide angiography (MUGA)
or echocardiography [42]. The left ventricular ejection
fraction is the ratio of the blood volume in the heart at the
end of systole to the volume at the end of diastole and is a
function of myocardial contractility and of peripheral
resistance. There is no clear advantage for using nuclear
angiography or echocardiography, although it is generally
believed that radionuclide angiography is a more objective
measurement and echocardiography is more widely avail-
able and does not carry the disadvantage of exposure to
radiation. Most experts agree that a drop in left ventricular
ejection fraction of more than 10 points from baseline and
to below 50% or below the institutional lower limit of
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normal indicates a significant drop in myocardial contrac-
tile function. However, it is important to realize that such a
drop in left ventricular ejection fraction is a late event in
the cancer drug-associated cardiotoxicity and therefore is
not detectable until significant cardiac damage already
occurred. The measurement of left ventricular contractile
function by myocardial strain Doppler echocardiography
might be a more sensitive measurement but needs valida-
tion and requires more sophisticated analysis than assess-
ment of the ejection fraction. Otherwise, measurement of
diastolic dysfunction and the contractile functional reserve
also seem to be a more sensitive measure for cancer drug-
associated cardiac toxicity. However, their use has been
limited by a low specificity for diastolic dysfunction and
the high technical efforts needed for the assessment of the
contractile reserve.
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